Literature DB >> 17149650

Provision of pharmaceuticals in Australian hospitals: equity of access?

Gisselle Gallego1, Susan J Taylor, Jo-anne E Brien.   

Abstract

In Australia, medicines are funded under a complex set of financial arrangements. Currently there are dual funding arrangements in public and private hospitals that can lead to differences in patient access to medications. There are considerable concerns about the consequences of the fragmentation and "lack of cohesion of the system". Some decision-makers consider there are inequities because of the funding models in place. What follows is a description of this system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17149650     DOI: 10.1007/s11096-006-9066-y

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  5 in total

1.  Incremental change in the Australian health care system.

Authors:  J Hall
Journal:  Health Aff (Millwood)       Date:  1999 May-Jun       Impact factor: 6.301

2.  The new health insurance rebate: an inefficient way of assisting public hospitals.

Authors:  S J Duckett; T J Jackson
Journal:  Med J Aust       Date:  2000-05-01       Impact factor: 7.738

3.  Confronting competing demands to improve quality: a five-country hospital survey.

Authors:  Robert J Blendon; Cathy Schoen; Catherine M DesRoches; Robin Osborn; Kinga Zapert; Elizabeth Raleigh
Journal:  Health Aff (Millwood)       Date:  2004 May-Jun       Impact factor: 6.301

4.  The subsidy of pharmaceuticals in Australia: processes and challenges.

Authors:  Lloyd Sansom
Journal:  Aust Health Rev       Date:  2004-11-08       Impact factor: 1.990

5.  Australian hospital services: an overview.

Authors:  S J Duckett
Journal:  Aust Health Rev       Date:  2002       Impact factor: 1.990

  5 in total
  2 in total

1.  Hospital drug and therapeutics committees in Australia: is there a role for economic evaluation at the institutional level?

Authors:  Gisselle Gallego
Journal:  Int J Clin Pharm       Date:  2011-12

2.  A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.

Authors:  Rajan Ragupathy; Katri Aaltonen; June Tordoff; Pauline Norris; David Reith
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.